Ranbir Kapoor’s entrepreneurial venture, ARKS, officially launches today with a debut collection of elevated essentials that ...

Indian celebrity-backed fashion brands struggle due to lack of clear brand identity, inconsistent quality, and market ...

Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity, ...

Permits have been filed for the construction of a 4-story residential building at 1848 Guerlain St. in the Parkchester neighborhood of the Bronx.

Scott and Federico are safe." In other moves, Nush is now the clear 5/1 second favourite behind Ray. Her odds to win have been cut from 6/1 to 5/1.

Metsera, a clinical-stage biotechnology firm, debuted on the Nasdaq Global Select Market today. After initially offering its common stock to the public at $18.00 per share, the company's shares opened ...

(“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity, overweight and related ...

NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog ...

Metsera, Inc MTSR IPO will take place January, 31 on the NASDAQ exchange under the ticker MTSR. The company is offering shares at an expected price between $15.00 and $17.00 per share with an insider ...

I’m neutral (hold) on MTSR’s IPO. New York, NY-based Metsera, Inc. was founded to develop a range of oral and injectable NuSH peptides to reduce obesity and overweight conditions. Management ...